Scientific Advisory Board

Pega-One is supported by a scientific advisory board, with world renowned experts in the field of clinical development of innovative oncology therapies.

Aurélien Marabelle MD, PhD, is a Senior Medical Oncologist in the Drug Development Department (DITEP), a group leader in Prof Laurence Zitvogel’s lab (INSERM U1015) and the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy. He joined the faculty in Oct 2014. He got a MSc & PhD in Oncology & Immunology from Ecole Normale Supérieure de Lyon, King’s College London & University of Lyon and did a post-doctoral fellowship in Prof Ronald Levy’s lab at Stanford University, California. Trained at the University of Paris VI medical school Dr. Marabelle received his medical degree from the University of Clermont-Ferrand. He completed his residency training in between Clermont-Ferrand & Lyon, followed by a clinical fellowship at Léon Bérard Cancer Center in Lyon. Dr Marabelle is a member of ASCO & AACR and a board-certified in Pediatric Oncology & Cell Therapy. 

David Feltquate MD, PhD, is Chief Medical Officer at Palleon Pharmaceuticals. Prior to joining Palleon, Dr. Feltquate was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Previously, he held numerous leadership positions at BMS where as the Nivolumab Clinical Head, he was responsible for the development of the first PD-1 inhibitor from proof of concept through initial registrations. Dr. Feltquate earned a B.S. in biology from the Massachusetts Institute of Technology and an M.D./Ph.D. (immunology) from University of Massachusetts Medical School. He completed internal medicine training at Dartmouth Hitchcock Medical Center and medical oncology training at Memorial Sloan Kettering Cancer Center

Steffen Heeger, MD, PhD, is an internationally recognized clinical development leader with a strong track record in the clinical development of antibody-based, targeted oncology drugs. His work was instrumental for the development of the blockbuster drug ERBITUX®, a monoclonal therapeutic antibody targeting EGFR, and for successful clinical development of other anti-cancer therapeutic antibodies, including tumor targeting CD19, CD38 and PSMA.